神经淋巴瘤病的临床表现、治疗与结局:一项系统综述
该系统综述纳入2004至2023年264项研究共459例神经淋巴瘤病(NL)患者,原发NL 197例,继发NL 262例。NL多表现为快速进展的不对称痛性多神经病,诊断主要依靠周围神经系统活检或FDG-PET(诊断率>90%)。中位总生存期18个月;原发NL无神经系统外并发疾病、ECOG<2及利妥昔单抗为基础的治疗为有利预后因素。
要点
- NL常表现为快速进展的不对称痛性多神经病,可累及周围神经、神经根、神经丛和脑神经。
- 诊断主要依靠周围神经系统活检或FDG-PET,诊断率高(>90%),但原发NL诊断延迟常见。
- 原发NL无神经系统外并发疾病、ECOG<2及利妥昔单抗为基础的治疗与更好预后相关。
核心结论
- 神经影像学进展尤其是FDG-PET有助于NL诊断且诊断率高,但原发NL诊断延迟仍常见。
- 以利妥昔单抗为基础的治疗改善NL结局。
- 研究结果可能有助于临床医生早期识别、预后分层和治疗NL。
研究设计与样本
- 系统综述,检索PubMed和Scopus数据库2004年至2023年文献,遵循PRISMA指南报告。
- 纳入报告明确诊断为NL的个体患者数据的研究,共纳入264项研究的459例NL病例。
- 提取临床、影像学、病理学和结局信息,采用log-rank检验和Cox比例风险模型进行单变量和多变量生存分析。
主要发现
- NL为恶性肿瘤首发表现(原发NL)197例;已知非霍奇金淋巴瘤的周围神经系统复发(继发NL)262例,中位复发时间12个月。
- 浸润结构包括周围神经(56%)、神经根(52%)、神经丛(33%)和脑神经(32%)。
- 从症状出现到确诊中位时间3个月,原发NL诊断延迟显著。
- 诊断主要依靠周围神经系统活检或FDG-PET,诊断率>90%;尸检诊断罕见(3%)。
- 大多数病例为B细胞淋巴瘤(90%);96%患者接受肿瘤导向治疗,通常为甲氨蝶呤或利妥昔单抗为基础的联合化疗;中位总生存期18个月。
关键数值与推荐
- 多变量分析中,原发NL无神经系统外并发疾病(HR 0.44;95%CI 0.25-0.78;p=0.005)、体能状态(ECOG<2,HR 0.30;95%CI 0.18-0.52;p<0.0001)和利妥昔单抗为基础的治疗(HR 0.46;95%CI 0.28-0.73;p=0.001)为有利预后标志。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neurolymphomatosis (NL) refers to lymphomatous infiltration of the peripheral nervous system (PNS). NL diagnosis and treatment are challenging given the broad differential diagnosis of peripheral neuropathy, the lack of larger cohorts, and the subsequent unavailability of prognostic factors or consensus therapy. This study aimed to define characteristics and prognostic factors of NL. METHODS: A systematic review of the literature (2004-2023) was performed using PubMed and Scopus databases and reported following PRISMA guidelines. Studies reporting individual patient data on cases with definitive NL diagnosis were included. Clinical, radiologic, pathologic, and outcome information were extracted. Univariable and multivariable survival analyses were performed using log-rank tests and Cox proportional hazard models. RESULTS: A total of 459 NL cases from 264 studies were accumulated. NL was the first manifestation of malignancy (primary NL) in 197 patients. PNS relapse of known non-Hodgkin lymphoma (secondary NL) occurred in 262 cases after a median 12 months. NL predominantly presented with rapidly deteriorating, asymmetric painful polyneuropathy. Infiltrated structures included peripheral nerves (56%), nerve roots (52%), plexus (33%), and cranial nerves (32%). Diagnosis was established at a median of 3 months after symptom onset with substantial delays in primary NL. It mainly relied on PNS biopsy or FDG-PET, which carried high diagnostic yields (>90%). Postmortem diagnoses were rare (3%). Most cases were classified as B-cell (90%) lymphomas. Tumor-directed therapy was administered in 96% of patients and typically consisted of methotrexate or rituximab-based polychemotherapy. The median overall survival was 18 months. Primary NL without concurrent systemic disease outside the nervous system (hazard ratio [HR]: 0.44; 95% CI 0.25-0.78; p = 0.005), performance status (ECOG <2, HR: 0.30; 95% CI 0.18-0.52; p < 0.0001), and rituximab-based treatment (HR: 0.46; 95% CI 0.28-0.73; p = 0.001) were identified as favorable prognostic markers on multivariable analysis when adjusting for clinical and sociodemographic parameters. DISCUSSION: Advances in neuroimaging modalities, particularly FDG-PET, facilitate NL diagnosis and offer a high diagnostic yield. Yet, diagnostic delays in primary NL remain common. Rituximab-based therapy improves NL outcome. Findings may assist clinicians in early recognition, prognostic stratification, and treatment of NL.
引用
- Kaulen LD, Hielscher T, Doubrovinskaia S, et al. Clinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review. Neurology. 2024. PMID: 39102613. doi:10.1212/WNL.0000000000209698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。